Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiosulfuric Acid SCHEMBL5710739 | 0.92 | MEN1 (0.54) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL5710744 | 0.92 | — | — | |
| Thiosulfuric Acid SCHEMBL230064 | 0.89 | MEN1 (0.44) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Thiosulfuric Acid SCHEMBL4209172 | 0.89 | MEN1 (0.44) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Thiosulfuric Acid SCHEMBL1195014 | 0.89 | ALDH1A1 (0.53) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Thiosulfuric Acid SCHEMBL30072761 | 0.88 | — | — | |
| Thiosulfuric Acid SCHEMBL29211051 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Thiosulfuric Acid SCHEMBL5529918 | 0.85 | MEN1 (0.47) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Bicarbonate SCHEMBL31485808 | 0.85 | MEN1 (0.47) | MEN1ALDH1A1TSHRKMT2ACA1 | |
| Thiosulfuric Acid SCHEMBL8208833 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| CN-116003239-B | Bicyclic diterpenoid derivative, preparation method and application thereof | 上海中医药大学 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024098692-A1 | WEE1 PROTEIN KINASE DEGRADING AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-118026948-A | Tri-aromatic ring compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-116003239-A | Bicyclic diterpenoid derivative, preparation method and application thereof | 上海中医药大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230097866-A1 | BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE | OHIO STATE INNOVATION FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| EP-3458468-B1 | STEROID 6.7.BETA.-EPOXIDES AS CHEMICAL INTERMEDIATES | NZP UK LTD (GB) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020239135-A1 | HIGH ANTICOAGULATION ACTIVITY COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION | 苏州鸿洋医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| EP-3494960-B1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | HELSINN HEALTHCARE SA (CH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3470086-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-0674634-A1 | PROCESS FOR PREPARING SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC (CA) | 1995-10-04 | — | — | EP | disclosed |
| US-5399770-A | Photoinitiator, preparation of printing plates, curing white paints | CIBA-GEIGY CORPORATION (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1994014802-A1 | PROCESS FOR PREPARING SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
| EP-0291234-B1 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5164371-A | HETEROCYCLIC KETONES | ICI AMERICAS INC. (US) | 1992-11-17 | — | — | US | disclosed |
| CN-1037519-A | HETEROCYCLIC KETONES | ICI AMERICA INC (US) | 1989-11-29 | — | — | CN | disclosed |
| EP-0291234-A2 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4272530-A | ESTROGENIC ACTIVITY | ROUSSEL UCLAF (FR) | 1981-06-09 | — | — | US | disclosed |
| US-4147695-A | 11β-Substituted-Δ9 -steroids | ROUSSEL UCLAF (FR) | 1979-04-03 | — | — | US | disclosed |
| US-3946046-A | Resolution of prostaglandin intermediates by means of oxazolidines | THE UPJOHN COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097866-A1 | BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE | TOP2A, TOP1, TOP2B | MEN1 3394/4885ALDH1A1 3472/4885TSHR 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.